Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39,390 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A 18F-FDG PET/CT-based deep learning-radiomics-clinical model for prediction of cervical lymph node metastasis in esophageal squamous cell carcinoma.
Yuan P, Huang ZH, Yang YH, Bao FC, Sun K, Chao FF, Liu TT, Zhang JJ, Xu JM, Li XN, Li F, Ma T, Li H, Li ZH, Zhang SF, Hu J, Qi Y. Yuan P, et al. Among authors: li f, li zh, li h, li xn. Cancer Imaging. 2024 Nov 12;24(1):153. doi: 10.1186/s40644-024-00799-0. Cancer Imaging. 2024. PMID: 39533388 Free PMC article.
Neoadjuvant camrelizumab followed by concurrent camrelizumab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, phase II study.
Sheng Y, Meng X, Zhang C, Shan Z, Li F, Wu B, Xu M, Li A, Guan L, Chen L, Sun S, Ma Y, Lu T, Zhao S, Fan Q, Qi Y, Wang F. Sheng Y, et al. Among authors: li f, li a. J Thorac Dis. 2024 Aug 31;16(8):5337-5347. doi: 10.21037/jtd-24-1141. Epub 2024 Aug 28. J Thorac Dis. 2024. PMID: 39268120 Free PMC article.
Predilection site and risk factor of second primary cancer: A pan-cancer analysis based on the SEER database.
Xiong S, Liang H, Liang P, Cai X, Li C, Zhong R, Li J, Cheng B, Zhu F, Ou L, Chen Z, Zhao Y, Deng H, Chen Z, Liu Z, Xie Z, Li F, He J, Liang W. Xiong S, et al. Among authors: li f, li c, li j. Chin Med J (Engl). 2023 Jun 20;136(12):1500-1502. doi: 10.1097/CM9.0000000000002681. Epub 2023 Apr 27. Chin Med J (Engl). 2023. PMID: 37101356 Free PMC article. No abstract available.
Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial.
Zhou HQ, Zhang YX, Chen G, Yu QT, Zhang H, Wu GW, Wu D, Lin YC, Zhu JF, Chen JH, Hu XH, Lan B, Zhou ZQ, Lin HF, Wang ZB, Lei XL, Pan SM, Chen LM, Zhang J, Kong TD, Yao JC, Zheng X, Li F, Zhang L, Fang WF. Zhou HQ, et al. Among authors: li f. Signal Transduct Target Ther. 2024 Aug 13;9(1):215. doi: 10.1038/s41392-024-01927-9. Signal Transduct Target Ther. 2024. PMID: 39134529 Free PMC article. Clinical Trial.
39,390 results
You have reached the last available page of results. Please see the User Guide for more information.